Apellis Pharmaceuticals Stock Buy Hold or Sell Recommendation
| APLS Stock | USD 26.33 1.08 3.94% |
Given the investment horizon of 90 days and your conservative risk appetite, our recommendation regarding Apellis Pharmaceuticals is 'Strong Sell'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Apellis Pharmaceuticals given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Apellis Pharmaceuticals, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Apellis Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Apellis Stock please use our How to Invest in Apellis Pharmaceuticals guide. Note, we conduct extensive research on individual companies such as Apellis and provide practical buy, sell, or hold advice based on investors' constraints. Apellis Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
Apellis |
Execute Apellis Pharmaceuticals Buy or Sell Advice
The Apellis recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Apellis Pharmaceuticals. Macroaxis does not own or have any residual interests in Apellis Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Apellis Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Apellis Pharmaceuticals Trading Alerts and Improvement Suggestions
| Apellis Pharmaceuticals generated a negative expected return over the last 90 days | |
| Apellis Pharmaceuticals has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 396.59 M. Net Loss for the year was (528.63 M) with profit before overhead, payroll, taxes, and interest of 297.94 M. | |
| Apellis Pharmaceuticals currently holds about 852.8 M in cash with (594.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.76. | |
| Apellis Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 86.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli for C3G and Primary IC-MPGN |
Apellis Pharmaceuticals Returns Distribution Density
The distribution of Apellis Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Apellis Pharmaceuticals' future price movements. The chart of the probability distribution of Apellis Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Apellis Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Apellis Pharmaceuticals returns is essential to provide solid investment advice for Apellis Pharmaceuticals.
| Mean Return | 0.13 | Value At Risk | -4.54 | Potential Upside | 4.84 | Standard Deviation | 3.74 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Apellis Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Apellis Stock Institutional Investors
The Apellis Pharmaceuticals' institutional investors refer to entities that pool money to purchase Apellis Pharmaceuticals' securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | Jennison Associates Llc | 2024-12-31 | 2.8 M | Ubs Group Ag | 2024-12-31 | 2.6 M | Fmr Inc | 2024-12-31 | 2.1 M | Braidwell Lp | 2024-12-31 | 2.1 M | Aqr Capital Management Llc | 2024-12-31 | 1.9 M | Geode Capital Management, Llc | 2024-12-31 | 1.8 M | Deutsche Bank Ag | 2024-12-31 | 1.8 M | Boxer Capital Llc | 2024-09-30 | 1.7 M | Bank Of America Corp | 2024-12-31 | 1.7 M | Venbio Select Advisor Llc | 2024-12-31 | 12.2 M | Ecor1 Capital, Llc | 2024-12-31 | 11.9 M |
Apellis Pharmaceuticals Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 215.1M | 74.7M | (88.7M) | (200.8M) | (180.7M) | (171.7M) | |
| Free Cash Flow | (165.9M) | (564.2M) | (515.3M) | (595.5M) | (536.0M) | (509.2M) | |
| Depreciation | 637K | 1.5M | 1.5M | 1.7M | 2.0M | 2.1M | |
| Other Non Cash Items | 15.8M | 6.3M | 61.6M | 26.4M | 30.4M | 15.4M | |
| Capital Expenditures | 5.4M | 1.1M | 1.5M | 773K | 889.0K | 1.6M | |
| Net Income | (344.9M) | (746.4M) | (652.2M) | (528.6M) | (475.8M) | (452.0M) | |
| End Period Cash Flow | 567.0M | 641.8M | 553.1M | 352.3M | 405.1M | 289.7M | |
| Change To Netincome | 37.8M | 148.6M | 274.3M | 152.1M | 174.9M | 183.7M |
Apellis Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Apellis Pharmaceuticals or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Apellis Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Apellis stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.12 | |
β | Beta against Dow Jones | 0.06 | |
σ | Overall volatility | 3.22 | |
Ir | Information ratio | 0.03 |
Apellis Pharmaceuticals Volatility Alert
Apellis Pharmaceuticals shows above-average downside volatility for the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Apellis Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Apellis Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Apellis Pharmaceuticals Fundamentals Vs Peers
Comparing Apellis Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Apellis Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Apellis Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Apellis Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Apellis Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Apellis Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Apellis Pharmaceuticals to competition |
Note: Disposition of 365 shares by Mark Delong of Apellis Pharmaceuticals at 29.5236 subject to Rule 16b-3 [view details]
Apellis Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Apellis . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 115797.0 | |||
| Daily Balance Of Power | (0.58) | |||
| Rate Of Daily Change | 0.96 | |||
| Day Median Price | 27.21 | |||
| Day Typical Price | 26.92 | |||
| Price Action Indicator | (1.42) | |||
| Period Momentum Indicator | (1.08) | |||
| Relative Strength Index | 43.62 |
About Apellis Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Apellis Pharmaceuticals? Buying financial instruments such as Apellis Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Apellis Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Impulse Thematic Idea Now
Impulse
Large corporations operating in retail, broadcasting, energy, airlines and telecom sectors. The Impulse theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Impulse Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Apellis Stock Analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.